LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Inicio・Lista de Acciones・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Cerrado

SectorSanidad

46.13 -1.64

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

45.77

Máximo

46.38

Métricas clave
By Trading Economics
Ingresos	36M -2.3M
Ventas	-3.9M 208M
P/B Media del Sector	48.435 50.102
BPA	0.21
Margen de beneficios	-1.104
Empleados	778
EBITDA	-72M 19M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+35.88% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-2.1M 2.8B
Apertura anterior	47.77
Cierre anterior	46.13

Supernus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 may 2026, 23:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

31 may 2026, 23:36 UTC

Charlas de Mercado

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 may 2026, 23:36 UTC

Charlas de Mercado

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 may 2026, 22:54 UTC

Adquisiciones, fusiones, absorciones

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 may 2026, 23:08 UTC

Adquisiciones, fusiones, absorciones

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 may 2026, 20:53 UTC

Ganancias

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 may 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 20:33 UTC

Charlas de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 may 2026, 20:11 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 19:47 UTC

Ganancias

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 may 2026, 19:36 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 may 2026, 19:22 UTC

Charlas de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 may 2026, 19:05 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 may 2026, 18:19 UTC

Charlas de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 may 2026, 18:12 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 may 2026, 18:11 UTC

Charlas de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 may 2026, 18:10 UTC

Charlas de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 may 2026, 17:55 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 17:55 UTC

Charlas de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 may 2026, 17:00 UTC

Ganancias

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

29 may 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

29 may 2026, 16:02 UTC

Charlas de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Supernus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

35.88% repunte

Estimación a 12 Meses

Media 62.75 USD 35.88%

Máximo 66 USD

Mínimo 55 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.